Neuroscience legend Steve Paul retires; Exclusive: GSK hires ex-Innate Pharma CEO for new position
If you’re in neuroscience, you’ve probably heard of him.
Few people have dipped a hand in as many neuroscience biotechs and government research units as Steve Paul, and he’s going out (nearly) on top.
The decadeslong CNS drug discovery and development veteran retired from his post as chief scientific officer and president of R&D at Karuna Therapeutics on Jan. 16, just weeks after inking a $14 billion exit to Bristol Myers Squibb.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.